Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder.
- Author:
Kiyokazu ATAKE
1
;
Reiji YOSHIMURA
;
Hikaru HORI
;
Asuka KATSUKI
;
Atsuko IKENOUCHI-SUGITA
;
Wakako UMENE-NAKANO
;
Jun NAKAMURA
Author Information
1. Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan. yoshi621@med.uoeh-u.ac.jp
- Publication Type:Original Article
- Keywords:
Duloxetine;
3-Methoxy-4-hydroxyphenylglycol;
Homovanillic acid;
Major depressive disorder;
Brain-derived neurotrophic factor
- MeSH:
Brain-Derived Neurotrophic Factor;
Depression;
Depressive Disorder, Major*;
Diagnostic and Statistical Manual of Mental Disorders;
Homovanillic Acid*;
Humans;
Norepinephrine*;
Plasma*;
Duloxetine Hydrochloride
- From:Clinical Psychopharmacology and Neuroscience
2014;12(1):37-40
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: We investigated the effects of duloxetine on the plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor (BDNF) in 64 patients with major depressive disorder (MDD). METHODS: Major depressive episode was diagnosed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV) according to the DSM-IV text revision (DSM-IV-TR) criteria. The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17). Blood sampling and clinical evaluation were performed on days 0, 28, and 56. RESULTS: Duloxetine treatment for 8 weeks significantly increased the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels but not the homovanillic acid (HVA) levels in responders with MDD. CONCLUSION: These results imply that noradrenaline plays an important role in alleviating depressive symptoms.
